Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hypertension
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hypertension
    Obesity Leading Risk Factor of Left Atrial Enlargement During Aging - (DGNews)
    TopAbstracts in Hypertension 11/25/2009 - (DGNews)
    Team-Based Care Involving a Pharmacist Improves Blood Pressure Control - (DGNews)
    Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study - (BMJ)
    TopAbstracts in Hypertension 11/18/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Hypertension
    • State of the Art in Pulmonary Arterial Hypertension
    • Medication Use for Diabetes, Hypertension, and Hypercholesterolemia from 1988-1994 to 2001-2006
      Optimizing Antihypertensive Therapy and Health and Economic Outcomes in a Managed Care Environment
      Treating Coronary Artery Disease in Vulnerable Adults
      Thrombotic Thrombocytopenic Purpura: The Masquerader

      Webcasts/CME archive

       Recent cases - Hypertension
        A Woman with Swollen Fingers and New-Onset Hypertension and Renal Failure
        Hypertension
        Medical Management of a Pregnancy Woman with Moderate Renal Insufficiency and Superimposed Preclampsia
        Malignant Hypertension and Acute Aortic Dissection Associated with Caffeine-Based Ephedra-Free Dietary Supplements: A Case Report
        Giant Right Coronary Artery Aneurysm: Case Report and Literature Review

        Cases archive
          




        my personal edition > hypertension > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Carvedilol Reduces But Valsartan May Increase Sexual Activity In Hypertensive Men

        A DGReview of :"Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study"
        American Journal of Hypertension

        02/01/2001
        By David Loshak


        The combined alpha-beta antagonist carvedilol induces a chronic reduction of sexual activity whereas valsartan, an angiotensin II antagonist, not only does not significantly reduce sexual activity but may even increase it.

        This is the chief finding of a double-blind cross-over study by researchers at the University of Pavia, Italy. They compared the effect of antihypertensive treatment with the two agents on the sexual activity of previously untreated hypertensive men.

        They enrolled 160 newly diagnosed hypertensive men aged 40 to 49 years, all married and without any previous sexual dysfunction.

        After four weeks on placebo, the patients were divided into two groups. In the first, 120 were randomised to receive carvedilol 50 mg once daily or valsartan 80 mg once daily for 16 weeks. This period was followed by another four-week placebo period, followed by the alternative regimen for a further 16 weeks.

        In the second group, 40 patients received placebo according to a single-blind design for 16 weeks.

        At the screening visit and every four weeks thereafter, blood pressure was evaluated and patients completed questionnaires about their sexual activity.

        Both drugs lowered blood pressure significantly, normalisation being 48 percent with valsartan and 45 percent with carvedilol. Likewise, during the first month of therapy, sexual activity (frequency of sexual intercourse) declined with both drugs as compared with baseline.

        That decrease, however, was statistically significant only with carvedilol. Frequency of intercourse fell from 8.2 to 4.4 occasions. With valsartan, the decline, from 8.3 to 6.6, was not statistically significant.

        Moreover, as treatment continued beyond the first four weeks, sexual activity declined still further with carvedilol to 3.7 occasions per month but rose with valsartan, to 10.2. These findings were confirmed by the cross-over data.

        Erectile dysfunction was a complaint of 15 patients treated with carvedilol (13.5 percent) but only one patient given valsartan (0.9 percent), as well as one patient in the placebo group.
        American Journal of Hypertension 2001; 14 (1): 27-31. "Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send